John Lowe III
John Lowe, III has 30 years experience as a medicinal chemist at Pfizer Inc. in the antibiotics, inflammation, lead discovery, and neuroscience therapeutic areas. He is the Co-discoverer of the antipsychotic drug ziprasidone (Geodon) and the first non-peptide substance P (NK1) receptor antagonist, CP-96,345. Chair of the Gordon Research Conference on Medicinal Chemistry, 2006. As a consultant at JL3 Pharma, John’s goal is to provide valuable advice on drug discovery projects in the area of pharmaceutical research and his specialties include medicinal chemistry, drug design, and synthetic organic chemistry.